PositiveID Publishes Report on Its BioThreat Detection and Diagnostics Solutions
23 January 2014 - 1:30PM
PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a
developer of biological detection and diagnostics solutions, today
announced that it has published a report on the current market
opportunities for its homeland security and medical diagnostics
technologies.
"The bio-detection market has seen a surge in funding over the
past decade," stated William J. Caragol, Chairman and CEO of
PositiveID. "This increase can be directly attributed to events
that have occurred since the beginning of the 21st century such as
the Anthrax scare in 2001, the SARS outbreak in 2003, the ricin
letters in 2004, the H1N1 health crisis in 2009, and most recently
the concern over Syrian and North Korean biological and chemical
weapons programs."
Mr. Caragol continued, "The urgent requirement for public
healthcare and homeland security agencies to institute an early
detection system for bio-terrorist attacks and infectious disease
outbreaks is at hand. PositiveID's technologies reduce the
time to both detect the presence of a threat and diagnose affected
persons, enabling the deployment of countermeasures and vaccines in
a time frame where casualties and fatalities can be drastically
reduced. Our products are capable of revolutionizing not only
our nation's response to bioterrorism but also improving medical
testing at the point of need."
A copy of the report is available on PositiveID's website at
http://www.positiveidcorp.com/files/PositiveID_Market_Opportunities_2014-01-24.pdf.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and
developer of biological detection systems for America's homeland
defense industry as well as rapid biological testing. PositiveID is
focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in
order to detect biological threats at high-value locations, as well
as analyze samples in a medical environment. For more information
on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including,
without limitation, the likelihood that the Company's products are
capable of revolutionizing not only our nation's response to
bioterrorism but also improving medical testing at the point of
need; and all statements in this press release constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected
results. These risks and uncertainties include, without limitation,
the Company's ability to target the bio-threat detection and rapid
medical testing sectors; as well as other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings
with the Securities and Exchange Commission, including those set
forth in the Company's 10-K filed on March 28, 2012, as amended on
May 4, 2012, and 10-Qs filed on November 16, 2012, August 20, 2012,
as amended on September 12, 2012, and May 14, 2012, under the
caption "Risk Factors." The Company undertakes no obligation to
update or release any revisions to these forward-looking statements
to reflect events or circumstances after the date of this statement
or to reflect the occurrence of unanticipated events, except as
required by law.
CONTACT: PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com